title: Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast.
abstract: Infiltrating ductal mammary carcinomas are histologically graded according to their extent of differentiation. Well-differentiated, grade I, tumours have low proliferative activity, usually form tubules and exhibit little nuclear pleomorphism. Despite an apparently reassuring morphology, 10-15% of grade I ductal carcinomas metastasize, albeit after a prolonged period. Recent evidence supports the view that evolution to higher grade malignancies occurs rarely and that grade I tumours are biologically distinct from grade III tumours. We have examined a series of 148 grade I ductal carcinomas in order to ascertain whether information about the level of expression of cyclin D1, p27, p53, oestrogen receptor status (ER) or proliferative activity could be used to identify those patients with a poor outcome. The majority of tumours expressed high levels of cyclin D1, p27 and ER, low levels of p53 and had low Ki-67 expression and mitotic counts. Cyclin D1, p27 and ER expression were all significantly correlated with each other but not with p53 (cyclin D1 correlation with ER, p = 0.01; cyclin D1 correlation with p27 and ER correlation with p27 both p < 0.0001). Cyclin D1 and ER were also both correlated with Ki-67 (p = 0.01 and p < 0.0001) but not with mitotic count. Our results suggest that cyclin D1, ER and p27 are all markers of well-differentiated tumours and that their detection is related to proliferative activity in a manner reflecting their functional role within the normal cell cycle. However, none of the proteins or markers of proliferative activity were sensitive enough to predict which patients were likely to have a poor outcome.
authors.affiliation: Hedley Atkins/ICRF Breast Pathology, Laboratory, Guy's Hospital, London, United Kingdom.
authors.forename: A C
authors.initials: AC
authors.lastname: Leong
authors.forename: A M
authors.initials: AM
authors.lastname: Hanby
authors.forename: H W
authors.initials: HW
authors.lastname: Potts
authors.forename: D S
authors.initials: DS
authors.lastname: Tan
authors.forename: D
authors.initials: D
authors.lastname: Skilton
authors.forename: K
authors.initials: K
authors.lastname: Ryder
authors.forename: W H
authors.initials: WH
authors.lastname: Harris
authors.forename: R D
authors.initials: RD
authors.lastname: Liebmann
authors.forename: D M
authors.initials: DM
authors.lastname: Barnes
authors.forename: C E
authors.initials: CE
authors.lastname: Gillett
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000473:pathology; D018797:Cell Cycle Proteins / Q000378:metabolism*; D002455:Cell Division; D019938:Cyclin D1 / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D008840:Microfilament Proteins / Q000378:metabolism; D008875:Middle Aged; D008940:Mitotic Index; D009124:Muscle Proteins; D010641:Phenotype; D011960:Receptors, Estrogen / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D018797:Cell Cycle Proteins; D019394:Ki-67 Antigen; D008840:Microfilament Proteins; D009124:Muscle Proteins; D011960:Receptors, Estrogen; C058992:Tagln protein, mouse; D016159:Tumor Suppressor Protein p53; D019938:Cyclin D1